Despite increasing investments and rising costs, the pharmaceutical industry's internal rate of return (IRR) from research and development (R&D) has been on a downward trajectory for decades. Recently, however, an analysis indicates the possibility of a resurgence in R&D returns, a
Introducing Ivan Kairatov, a distinguished authority in biopharmaceutical innovation and technological advancements. With extensive experience in research and development, Ivan provides a unique perspective on the acquisition of Althea by PCI Pharma. This interview delves into how such strategic
The current landscape of the scientific and pharmaceutical industries presents a fascinating blend of unprecedented advancements and complex challenges that continue to redefine the sector. As these industries evolve, they encounter critical opportunities for growth alongside significant hurdles
In this exclusive conversation, we delve into the complexities of the cell culture market with Ivan Kairatov, a seasoned biopharma expert. His insights into the tech-driven evolution of this sector highlight the potential for innovation in drug discovery and development. How do you perceive the
Fructose, a common sugar found in many everyday foods, has been discovered to indirectly contribute to the growth of tumors. This potentially transformative finding opens new avenues for cancer treatment. Building upon early twentieth-century research by German physiologist Otto Warburg, which
In the quest to understand and treat cancer, researchers have faced significant obstacles with traditional models such as two-dimensional cell cultures and in vivo xenografts. These methods, while useful in their own right, often fall short in accurately replicating the complex architecture and
